Furthermore, Hu et al. (2016) reported that in an insulin-resistant rat model of NASH and cirrhosis, metformin improves the hepatic condition via IRS2/PI3K/Akt signaling, with increased phosphorylation and activation of Akt [42]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.